25 years of supportive anti-infective treatment in haemato-oncology


Authors: L. Drgoňa
Authors‘ workplace: Klinika onkohematológie, Lekárska fakulta Univerzity Komenského a Národný onkologický ústav, Bratislava
Published in: Transfuze Hematol. dnes,25, 2019, No. 1, p. 30-33.
Category:

Overview

Developments and advances in the diagnosis and treatment of haematological malignancies are closely linked to progress in supportive care. Treatment is associated with toxicity and adverse events that can fundamentally influence the effect of antineoplastic therapy. The aim of anti-infective support is to reduce infectious complications preventively or causally once they manifest. Its importance is confirmed by their incorporation into guidelines governing the complex treatment of patients with haematological malignancies. Modern strategies for the prevention and treatment of infections are among the factors have improved not only quality of life but also survival in our patients.

Keywords:

supportive therapy – febrile neutropenia – haematological malignancies – infections – growth factors – invasive fungal infections


Sources

1. Kouba M, Lukášová M. Prevence a léčba infekčních komplikací v hematoonkologii. Vnitř Lék 2012;58(suppl. 2):56–60.

2. Bodey GP, Bucley M, Sathe YS, et al. Quantitative relationship between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 1966;61:328.

3. Pizzo PA, Robichaud KJ, Gill FA, et al. Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia. Am J Med 1982;72:101–111.

4. Pizzo PA. Management of patients with cancer and treatment-induced neutropenia. N Engl J Med 1993;328:1323–1332.

5. Krcméry V Jr., Danisovicová A, Drgona L, et al. Ceftriaxone versus ceftazidime plus aminoglycoside therapy for infections in patients with neutropenia after cytotoxic chemotherapy. Short communication. Neoplasma 1993;40(2):103–105.

6. http://www.leukemia-cell.org/index.php?pg=home--projekty--infekce, (4.11.2018).

7. Kolář M, Faber E, Lochmannová J jr., et al. Antibiotická léčba pacientů s febrilní neutropenií. Transfuze Hematol dnes 2002;1:20–24.

8. Drgoňa Ľ. Febrilná neutropénia. Onkológia (Bratisl) 2012;7(1):20–23.

9. Cometta A, Marchetti O, Calandra T. Empirical use of anti-Gram-positive antibiotics in febrile neutropaenic cancer patients with acute leukaemia. Eur J Cancer Suppl 2007;5:23–31.

10. Mikulska M, Viscoli C, Orasch C, et al. for the Fourth European Conference on Infections in Leukemia Group (ECIL-4), a joint venture of EBMT, EORTC, ICHS, ELN and ESGICH/ESCMID. Aetiology and resistance in bacteraemias among adult and paediatric haematology and cancer patients. J Infect 2014;68(4):321–331.

11. Averbuch D, Cordonnier C, Livermore DM, et al. on behalf of ECIL4, a joint venture of EBMT, EORTC, ICHS, ESGICH/ESCMID and ELN. Targeted therapy against multi-resistant bacteria in leukemic and hematopoietic stem cell transplant recipients – guidelines of the 4th European Conference on Infections in Leukemia. Haematologica 2013:98(12):1836–1847.

12. Averbuch D, Orasch C, Cordonnier C, et al. on behalf of ECIL4, a joint venture of EBMT, EORTC, ICHS, ESGICH/ESCMID and ELN. European guidelines for empirical antibacterial therapy for febrile neutropenic patients in the era of growing resistance: summary of the 2011 4th European Conference on Infections in Leukemia. Haematologica 2013:98(12):1826–1835.

13. Kern WV, Cometta A, DeBock R, et al. Oral versus intravenous empirical antimicrobial therapy for fever in patients with granulocytopenia who are receiving cancer chemotherapy. IATCG EORTC. N Engl J Med 1999;341:312–318.

14. Klastersky J, Paesmans M, Rubenstein EB, et al. The Multinational Association for Supportive Care in Cancer risk index: a multinational scoring system for identifying low-risk febrile, neutropenic cancer patients. J Clin Oncol 2000;18:3038–3051.

15. Orasch C, Averbuch D, Mikulska M, et al. for the 4th European Conference on Infections in Leukemia. Discontinuation of empirical antibiotic therapy in neutropenic leukaemia patients with fever of unknown origin is ethical. Clin Microbiol Infect 2015;21:e25–e27.

16. Tissot F, Agrawal S, Pagano L, et al. ECIL-6 guidelines for the treat-
ment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients. Haematologica 2017:102(3):433–444.

17. Maertens J, Theunissen K, Verhoef G, et al. Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study. Clin Infect Dis 2005;41:1242–1250.

18. Bezdicek M, Lengerova M, Ricna D, et al. Rapid detection of fungal pathogens in bronchoalveolar lavage samples using panfungal PCR combined with high resolution melting analysis. Med Mycol 2016;54(7):714–724.

19. Čerňan M, Szotkowski T, Kolář M, et al. Infekčné komplikácie behom indukčnej liečby akútnej myeloblastovej leukémie bez použitia antibiotickej profylaxie. Transfuze Hematol dnes 2015;21(1):14–23.

20. Cordonnier C, Cesaro S, Maschmeyer G, et al. Pneumocystis jirovecii pneumonia: still a concern in patients with haematological malignancies and stem cell transplant recipients. J Antimicrob Chemother 2016;71:2379–2385.

21. Cornely OA, Maertens J, Drew JW, et al. Posaconazole versus fluconazole or itraconazole prophylaxis in patiens with neutropenia. N Engl J Med 2007;356:348–359.

22. Ullman AJ, Lipton JH, Vesole DH, et al. Posaconazole versus fluconazole for prophylaxis for invasive fungal infections in allogeneic hematopoietic stem cell transplant recipients with graft-versus-host disease: results of a multicenter trial. N Engl J Med 2007;356:335–347.

23. Green ML, Leisenring W, Stachel D, et al. Efficacy of a viral load-based, risk- adapted, preemptive treatment strategy for prevention of cytomegalovirus disease af- ter hematopoietic cell transplantation. Biol Blood Marrow Transplant 2012;18:1687–1699.

24. Marty F, Ljungman P, Chemaly RF, et al. Letermovir prophylaxis for cytomegalovirus in hematopoietic-cell transplantation. N Engl
J Med 2017;377:2433–2444.

25. Trillet-Lenoir V, Green J, Manegold C, et al. Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy. Eur J Cancer 1993;29A:319–324.

26. Wang L, Baser O, Kutikova L, et al. The impact of primary prophylaxis with granulocyte colony-stimulating factors on febrile neutropenia during chemotherapy: a systematic review and meta-analysis of randomized controlled trials. Support Care Cancer 2015;23(11):3131–3140.

27. Gascon P, Fuhr U, Sorgel F, et al. Development of a new G-CSF product based on biosimilarity assessment. Ann Oncol 2010;21:1419–1429.

28. Drgoňa Ľ, Trupl J, Mikula J, et al. Diagnostika a liečba invazívnych mykóz –inovovaná verzia 1.2008. Antibiotiká a rezistencia 2008;3(7):5–13.

29. Ráčil Z, Haber J, Drgoňa L, et al. Primární profylaxe invazivních mykotických infekcií u hematoonkologických nemocných – doporučení odborníku s podporou CELL, CHS JEP, COS JEP, SOS SLS. Postgrad Med 2009;11(Suppl.1):39–42.

30. Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002;347:408–415.

31. Cordonnier C, Pautas C, Maury S, et al. Empirical versus preemptive antifungal therapy for high-risk, febrile, neutropenic patients: a randomized, controlled trial. Clin Infect Dis 2009;48:1042–1051.

32. Ráčil Z, Haber J, Drgoňa Ľ, et al. Empirická antimykotická léčba febrilní neutropenie u nemocných s hematologickou malignitou – doporučení odborníků – s podporou CELL, ČHS ČLS JEP, ČOS ČLS JEP, SCHS SLS. Postgrad Med 2010;132(Suppl. 5):23–25.

33. Drgona L, Gudiol C, Lanini S, Salzberger B, Ippolito G, Mikulska M. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an Infectious Diseases perspective (Agents targeting lymphoid or myeloid cells surface antigens [II]: CD22, CD30, CD33, CD38, CD40, SLAMF-7 and CCR4). Clin Microbiol Inf 2018;24(Supl2):S83–S94.

Labels
Haematology Internal medicine Clinical oncology

Article was published in

Transfusion and Haematology Today

Issue 1

2019 Issue 1

Most read in this issue

This topic is also in:


Login
Forgotten password

Don‘t have an account?  Create new account

Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account